[Recommendations for management of antiphospholipid syndrome in China].

Zhao, J L; Shen, H L; Chai, K X; Yang, C D; Zhao, Yan

Zhao, J L; Shen, H L; Chai, K X; Yang, C D; Zhao, Yan.

Afiliação

Zhao JL; Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology,State Key Laboratory of Comp
Shen HL; Department of Rheumatology and Immunology, Lanzhou University Second Hospital, Lanzhou 730099, China.
Chai KX; Department of Rheumatology and Immunology, Affiliated Hospital of Qinghai University, Xining 810016, China.
Yang CD; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China.
Zhao Y; Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology,State Key Laboratory of Comp

Zhonghua Nei Ke Za Zhi ; 61(9): 1000-1007, 2022 Sep 01.

Article em Zh | MEDLINE | ID: mdl-36008292

Assuntos

Síndrome Antifosfolipídica; Trombose; Anticorpos Antifosfolipídeos; Síndrome Antifosfolipídica/complicações; Síndrome Antifosfolipídica/diagnóstico; Síndrome Antifosfolipídica/terapia; China; Feminino; Humanos; Gravidez; Medição de Risco; Trombose/complicações

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trombose / Síndrome Antifosfolipídica Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies / Screening_studies Limite: Female / Humans / Pregnancy País/Região como assunto: Asia Idioma: Zh Revista: Zhonghua Nei Ke Za Zhi Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google